99 related articles for article (PubMed ID: 16612149)
21. [Radiotherapy for head and neck cancer].
Nishio M
Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Sep; 64(7):379-86. PubMed ID: 15688743
[TBL] [Abstract][Full Text] [Related]
22. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult.
Ho KF; Fowler JF; Sykes AJ; Yap BK; Lee LW; Slevin NJ
Acta Oncol; 2009; 48(3):431-9. PubMed ID: 18781445
[TBL] [Abstract][Full Text] [Related]
23. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
Byhardt RW
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
[TBL] [Abstract][Full Text] [Related]
24. Advanced head and neck carcinoma in women: treatment outcomes may not improve with accelerated hyperfractionated radiotherapy.
Leborgne F; Leborgne JH; Fowler JF; Zubizarreta E; Mezzera J
Cancer; 2001 Jun; 91(12):2353-60. PubMed ID: 11413525
[TBL] [Abstract][Full Text] [Related]
25. Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain.
Marcu LG
Cancer Treat Rev; 2010 Dec; 36(8):606-14. PubMed ID: 20494524
[TBL] [Abstract][Full Text] [Related]
26. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature.
Kong C; Guo WJ; Zha WW; Zhu XZ; Huang SF; Zhang YW; Xu JH; He X
Lung Cancer; 2014 Apr; 84(1):7-12. PubMed ID: 24548340
[TBL] [Abstract][Full Text] [Related]
27. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.
Leborgne F; Zubizarreta E; Fowler J; Ortega B; Mezzera J; Deus JL; Leborgne JH
Int J Cancer; 2000 Apr; 90(2):80-91. PubMed ID: 10814958
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy: the last 25 years.
Russell NS; Bartelink H
Cancer Treat Rev; 1999 Dec; 25(6):365-76. PubMed ID: 10644502
[TBL] [Abstract][Full Text] [Related]
29. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
[TBL] [Abstract][Full Text] [Related]
30. [Chemoradiotherapy. Therapeutic indications: the doctor's point of view].
Natale D; Orlando D
Suppl Tumori; 2004; 3(4):S123-4. PubMed ID: 15206236
[No Abstract] [Full Text] [Related]
31. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C; Eberhardt W; Graupner B; Theegarten D; Gauler T; Freitag L; Abu Jawad J; Wohlschlaeger J; Welter S; Stamatis G; Stuschke M
Eur J Cancer; 2013 Jun; 49(9):2107-15. PubMed ID: 23510803
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiotherapy for nonsmall cell lung cancer.
Ball D
Curr Opin Pulm Med; 2008 Jul; 14(4):297-302. PubMed ID: 18520262
[TBL] [Abstract][Full Text] [Related]
33. [Clinical application of altered fractionation theory].
Sakata K; Someya M; Nakata K; Takagi M; Hareyama M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1823-6. PubMed ID: 19011329
[TBL] [Abstract][Full Text] [Related]
34. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
Onimaru R; Fujino M; Yamazaki K; Onodera Y; Taguchi H; Katoh N; Hommura F; Oizumi S; Nishimura M; Shirato H
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):374-81. PubMed ID: 18029106
[TBL] [Abstract][Full Text] [Related]
35. [Therapeutic gain factor of multiple fractions per day].
Kanehira C; Mochizuki S
Gan No Rinsho; 1988 Oct; 34(13):1757-63. PubMed ID: 3199511
[TBL] [Abstract][Full Text] [Related]
36. PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial.
Bütof R; Simon M; Löck S; Troost EGC; Appold S; Krause M; Baumann M
Trials; 2017 Dec; 18(1):608. PubMed ID: 29262836
[TBL] [Abstract][Full Text] [Related]
37. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
Krstevska V; Crvenkova S
Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
[TBL] [Abstract][Full Text] [Related]
38. A novel dose-volume metric for optimizing therapeutic ratio through fractionation: retrospective analysis of lung cancer treatments.
Keller H; Hope A; Meier G; Davison M
Med Phys; 2013 Aug; 40(8):084101. PubMed ID: 23927363
[TBL] [Abstract][Full Text] [Related]
39. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck.
Mendenhall WM; Riggs CE; Amdur RJ; Hinerman RW; Villaret DB
Laryngoscope; 2003 Mar; 113(3):546-51. PubMed ID: 12616212
[TBL] [Abstract][Full Text] [Related]
40. Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology.
Yang Y; Xing L
Med Phys; 2005 Dec; 32(12):3666-77. PubMed ID: 16475766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
